CGEN (Compugen) Likuiditas cepet

Compugen Ltd. (CGEN) is scaling its AI-driven R&D system for antibody discovery, generating revenue through licenses and payments from pharma behemoths. The business's success relies on the patent protection of biomarkers and clinical trial results. The current metric stands at 5.55. The price chart below illustrates the price action of this high-tech biotech firm, which attracts leading bioinformaticians with advanced computing and stock options.

For the biotechnology business of Compugen Ltd. (CGEN), which develops AI algorithms for cancer immunotherapy, this indicator serves as a measure of immediate solvency. The metric gauges the company's ability to settle its obligations using only cash and accounts receivable, excluding inventory. By analyzing the quick ratio on the GURU.Markets chart, an investor assesses the issuer's actual margin of safety. Consistently high values confirm the absence of default risk, although an excessive cash balance may signal inefficient capital utilization.